Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Oct 1;97(2):125-132.
doi: 10.1097/QAI.0000000000003471.

Peer-Delivered HIV Self-Testing, Sexually Transmitted Infection Self-Sampling, and Pre-exposure Prophylaxis for Transgender Women in Uganda: A Randomized Trial

Affiliations
Randomized Controlled Trial

Peer-Delivered HIV Self-Testing, Sexually Transmitted Infection Self-Sampling, and Pre-exposure Prophylaxis for Transgender Women in Uganda: A Randomized Trial

Andrew Mujugira et al. J Acquir Immune Defic Syndr. .

Abstract

Background: Peer-delivered HIV self-testing (HIVST) and sexually transmitted infection self-sampling (STISS) may promote adherence to oral pre-exposure prophylaxis (PrEP), but no studies have analyzed this approach among transgender women (TGW) in sub-Saharan Africa.

Setting: The Peer study was a cluster randomized trial in Uganda (October 2020-July 2022; NCT04328025).

Methods: Ten TGW peer groups, each with 1 TGW peer and 8 TGW, were randomized 1:1 to receive quarterly in-clinic HIV testing with PrEP refills as standard-of-care (SOC) or SOC plus monthly peer delivery of oral-fluid HIVST, STISS, and PrEP refills (intervention). Participants were followed for 12 months. The primary outcome was PrEP adherence.

Results: We screened 85 TGW and enrolled 82 (41 per arm). The median age was 22 years (interquartile range [IQR] 20-24). Twelve-month retention was 88% (72/82). At the 3, 6, 9, and 12-month clinic visits, 10%, 5%, 5%, and 0% of TGW in the intervention arm had TFV-DP levels ≥700 fmol/punch, versus 7%, 15%, 7%, and 2% in the SOC arm, respectively (P = 0.18). At all visits, any detectable TFV-DP levels were significantly higher in SOC than the peer delivery group (P < 0.04). PrEP adherence was associated with sex work (incidence rate ratio 6.93; 95% CI: 2.33 to 20.60) and >10 years of schooling (incidence rate ratio 2.35; 95% CI: 1.14 to 4.84). There was a strong correlation between tenofovir detection in dried blood spots and urine (P < 0.001). No HIV seroconversions occurred.

Conclusions: Peer-delivered HIVST and STISS did not increase low levels of oral PrEP adherence among TGW in Uganda. Long-acting PrEP formulations should be considered for this population.

PubMed Disclaimer

Conflict of interest statement

The research reported in this publication was supported by the National Institute of Mental Health of the National Institutes of Health under Grant Number R34MH121084 to A.M. A.M. received research funding outside the submitted work from Gilead Sciences, Inc. J.E.H. is a consultant for Merck. None of the remaining authors declared any conflict of interest. The authors have no funding or conflicts of interest to disclose.

References

    1. UNAIDS. AIDS TARGETS. Prevailing against pandemics by putting people at the centre. UNAIDS; 2022; 2025. https://aidstargets2025.unaids.org/assets/images/prevailing-against-pand.... Accessed March 6, 2023.
    1. UNAIDS. Seizing the Moment: Tackling Entrenched Inequalities to End Epidemics; 2020.
    1. Stutterheim SE, van Dijk M, Wang H, et al. The worldwide burden of HIV in transgender individuals: an updated systematic review and meta-analysis. PLoS One. 2021;16:e0260063. - PMC - PubMed
    1. Kimani M, van der Elst EM, Chiro O, et al. PrEP interest and HIV-1 incidence among MSM and transgender women in coastal Kenya. J Int AIDS Soc. 2019;22:e25323. - PMC - PubMed
    1. Smith AD, Kimani J, Kabuti R, et al. HIV burden and correlates of infection among transfeminine people and cisgender men who have sex with men in Nairobi, Kenya: an observational study. Lancet HIV. 2021;8:e274–e283. - PubMed

Publication types

Substances

Associated data